Inari Medical, Inc. - NARI STOCK NEWS

Inari Medical (NASDAQ: NARI) announced its second-quarter financial results for 2021, reporting a record revenue of $63.5 million, an 11% increase sequentially, and a remarkable 150% year-over-year growth. The company obtained FDA clearance for FlowSaver, enhancing their treatment capabilities. Gross profit surged to $58.6 million with a gross margin of 92.4%. Operating expenses rose to $54.5 million, largely due to personnel growth. Inari expects 2021 revenue between $250 million and $255 million, raising previous guidance amid ongoing COVID-19 challenges.

Inari Medical, Inc. (NASDAQ: NARI), a medical device company specializing in venous diseases, announced its participation in the Canaccord Genuity 41st Annual Growth Conference. The presentation is scheduled for August 12, 2021, at 10:30 a.m. Eastern Time. Inari focuses on innovative catheter-based mechanical thrombectomy devices, such as the ClotTriever and FlowTriever systems, designed to treat deep vein thrombosis and pulmonary embolism effectively. Both devices have received FDA 510(k) clearance and CE Mark approval, emphasizing the company’s commitment to transforming patient care in venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) will announce its second quarter financial results on August 10, 2021. A conference call and webcast will follow at 1:30 p.m. PT to discuss the results and updates. Inari is known for its innovative medical devices aimed at treating venous diseases, including the ClotTriever and FlowTriever systems, both approved by the FDA and CE Mark for deep vein thrombosis and pulmonary embolism treatments, respectively. The company's focus remains on transforming patient care in venous thromboembolism.

Inari Medical, Inc. (NASDAQ: NARI) announced the appointment of Ms. Rebecca Chambers to its board of directors on June 22, 2021. Chambers, the CFO of Outset Medical, brings over a decade of healthcare leadership experience, including significant roles in investor relations for publicly traded companies. CEO Bill Hoffman stated that her expertise will be crucial as Inari continues to innovate in the venous thromboembolism treatment space. Inari develops minimally-invasive catheter-based devices for treating venous diseases, with products approved by the FDA and CE Mark.

Inari Medical, Inc. (NASDAQ: NARI) announced positive interim results from the ClotTriever Outcomes Registry (CLOUT) for the first 250 deep vein thrombosis (DVT) patients. The ClotTriever successfully removed 100% of blood clots in most cases without thrombolytic drugs, resulting in a median procedure time of 28 minutes and a modest blood loss of 50ml. This registry, the largest of its kind for mechanical thrombectomy treatment, highlights the effectiveness of ClotTriever, demonstrating a commitment to improving venous disease treatment.

Inari Medical, Inc. (NARI) reported first-quarter 2021 revenue of $57.4 million, a significant 113% increase compared to the same period last year and an 18% sequential growth. The company treated a record number of patients and enrolled the first patient in the FLAME study, a pivotal clinical trial for high-risk pulmonary embolism patients. Operating expenses rose to $45.1 million, largely due to increased personnel costs. Net income was $7.5 million, with an EPS of $0.15. The company forecasts 2021 revenue between $240 million to $250 million.

Inari Medical, Inc. (NASDAQ: NARI) announced its participation in the 2021 Bank of America Healthcare Conference on May 13, 2021, at 8:45 a.m. ET. This commercial-stage medical device company focuses on innovative products for venous diseases. Inari has developed two FDA-cleared devices: the ClotTriever for deep vein thrombosis and the FlowTriever for pulmonary embolism. Both systems are designed to effectively remove large clots without the need for thrombolytic drugs, enhancing patient outcomes in treating venous thromboembolism.

Inari Medical (NASDAQ: NARI) announced its financial results for Q1 2021 will be released on May 11, 2021. A conference call and webcast will occur the same day at 1:30 PM PT / 4:30 PM ET to discuss the results and recent highlights. Inari is a commercial-stage medical device company focused on innovative treatments for venous diseases. Its key products include the ClotTriever and FlowTriever systems, both FDA cleared and CE Mark approved for treating deep vein thrombosis and pulmonary embolism.

Inari Medical, Inc. (NASDAQ: NARI) has announced a global partnership with Aidoc, an AI solutions provider, to enhance the detection and treatment of pulmonary embolism (PE). The collaboration aims to integrate AI into clinical pathways, improving patient outcomes by rapidly triaging scans for suspected PE. With recent studies indicating that many high-risk PE patients do not receive timely care, this partnership seeks to leverage technology to optimize treatment pathways. Key executives from both companies highlighted the significance of AI in transforming patient care standards.